bluebird bio Stock Forecast, Price & News

bluebird bio (NASDAQ:BLUE) Frequently Asked Questions

Is bluebird bio a buy right now?

17 Wall Street analysts have issued "buy," "hold," and "sell" ratings for bluebird bio in the last year. There are currently 1 sell rating, 13 hold ratings, 2 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street analysts is that investors should "hold" bluebird bio stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in BLUE, but not buy additional shares or sell existing shares.
View analyst ratings for bluebird bio or view top-rated stocks.

How has bluebird bio's stock price been impacted by COVID-19 (Coronavirus)?

bluebird bio's stock was trading at $61.51 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, BLUE stock has decreased by 88.7% and is now trading at $6.93.
View which stocks have been most impacted by COVID-19.

When is bluebird bio's next earnings date?

bluebird bio is scheduled to release its next quarterly earnings announcement on Tuesday, February 22nd 2022.
View our earnings forecast for bluebird bio.

How were bluebird bio's earnings last quarter?

bluebird bio, Inc. (NASDAQ:BLUE) released its earnings results on Friday, November, 5th. The biotechnology company reported ($3.16) earnings per share for the quarter, missing the Zacks' consensus estimate of ($2.65) by $0.51. The biotechnology company had revenue of $22.70 million for the quarter, compared to the consensus estimate of $39.07 million. bluebird bio had a negative trailing twelve-month return on equity of 76.93% and a negative net margin of 1,610.78%. The firm's revenue was up 17.6% on a year-over-year basis. During the same period in the prior year, the business earned ($2.94) earnings per share.
View bluebird bio's earnings history.

What price target have analysts set for BLUE?

17 analysts have issued twelve-month price objectives for bluebird bio's stock. Their forecasts range from $10.00 to $39.00. On average, they anticipate bluebird bio's share price to reach $18.21 in the next year. This suggests a possible upside of 162.8% from the stock's current price.
View analysts' price targets for bluebird bio or view top-rated stocks among Wall Street analysts.

Who are bluebird bio's key executives?

bluebird bio's management team includes the following people:

• Nick Leschly, Director (LinkedIn Profile)
• Andrew Obenshain, President, Chief Executive Officer & Director (LinkedIn Profile)
• Gina R. Consylman, Chief Financial Officer
• Helen C. Fu, Secretary, Senior Vice President & General Counsel
• Mark T. Battaglini, Senior Vice President

What is Nick Leschly's approval rating as bluebird bio's CEO?

66 employees have rated bluebird bio CEO Nick Leschly on Glassdoor.com. Nick Leschly has an approval rating of 74% among bluebird bio's employees.

Who are some of bluebird bio's key competitors?

Some companies that are related to bluebird bio include Revolution Medicines (RVMD), Sana Biotechnology (SANA), Allogene Therapeutics (ALLO), Instil Bio (TIL), Vericel (VCEL), NanoString Technologies (NSTG), iTeos Therapeutics (ITOS), Editas Medicine (EDIT), Alector (ALEC), Sorrento Therapeutics (SRNE), Atara Biotherapeutics (ATRA), Krystal Biotech (KRYS), C4 Therapeutics (CCCC), REGENXBIO (RGNX) and Inhibrx (INBX).
View all of BLUE's competitors.

What other stocks do shareholders of bluebird bio own?

Based on aggregate information from My MarketBeat watchlists, some companies that other bluebird bio investors own include OPKO Health (OPK), BioMarin Pharmaceutical (BMRN), Puma Biotechnology (PBYI), NVIDIA (NVDA), Gilead Sciences (GILD), (CELG), Incyte (INCY), Micron Technology (MU), Alibaba Group (BABA) and (MDVN) (MDVN).

What is bluebird bio's stock symbol?

bluebird bio trades on the NASDAQ under the ticker symbol "BLUE."

Who are bluebird bio's major shareholders?

bluebird bio's stock is owned by many different institutional and retail investors. Top institutional shareholders include Cutler Group LP (0.00%). Company insiders that own bluebird bio stock include Alison Cecily Finger, Andrew Obenshain, David Davidson, Jason Cole, Jessica Whitten, Joanne Smith-Farrell, Katy Burnett, Kory James Wentworth, Nick Leschly and William D Baird III.
View institutional ownership trends for bluebird bio.

Which major investors are selling bluebird bio stock?

BLUE stock was sold by a variety of institutional investors in the last quarter, including Cutler Group LP. Company insiders that have sold bluebird bio company stock in the last year include Andrew Obenshain, Jason Cole, Jessica Whitten, Katy Burnett, Nick Leschly, and William D Baird III.
View insider buying and selling activity for bluebird bio or view top insider-selling stocks.

How do I buy shares of bluebird bio?

Shares of BLUE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is bluebird bio's stock price today?

One share of BLUE stock can currently be purchased for approximately $6.93.

How much money does bluebird bio make?

bluebird bio has a market capitalization of $485.84 million and generates $250.73 million in revenue each year. The biotechnology company earns $-618.70 million in net income (profit) each year or ($12.82) on an earnings per share basis.

How many employees does bluebird bio have?

bluebird bio employs 1,213 workers across the globe.

What is bluebird bio's official website?

The official website for bluebird bio is www.bluebirdbio.com.

Where are bluebird bio's headquarters?

bluebird bio is headquartered at 60 BINNEY STREET, CAMBRIDGE MA, 02142.

How can I contact bluebird bio?

bluebird bio's mailing address is 60 BINNEY STREET, CAMBRIDGE MA, 02142. The biotechnology company can be reached via phone at (339) 499-9300 or via email at [email protected].